drugset / Trial / NCT00003897
Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma
Phase 1
Completed
18 enrolled
University of Wisconsin, Madison
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Vaccines made from gp100 and sargramostim may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy with gp100 and/or sargramostim in treating patients who have malignant melanoma.
Timeline
- Start
- 1999-05
- Primary completion
- 2001-03
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gp100 antigen | Peptide | — | Other |
| Subject | sargramostim | Protein / enzyme biologic | — | Other |